It is our pleasure to announce that the first International Conference on Myeolid Cells and HIV is tentatively scheduled to take place on 1 - 3 September 2018 in Stresa, Italy
Over the years, eradication of HIV-1 has become more and more complex with the majority of research focusing on T cell reservoirs. However, myeloid cells are permissive to HIV-1 infection in vitro and in vivo yet the contribution of myeloid cells to HIV-1 persistence in the face of suppressive ART, is an understudied area. The source of viral rebound when treatment is interrupted, is not well understood. Furthermore, it is unclear what assays have the greatest ability to inform on the reservoirs that maintain HIV-1 persistence under ART.
The goal of the International Conference on Myeloid Cells & HIV 2018 is to assemble researchers and healthcare professionals to share and discuss the latest knowledge and advances in the field of HIV reservoirs and move the field forward.
Delegates will be provided with a unique opportunity to identify current roadblocks and to outline future research needed to overcome these barriers, and will ultimately, catalyze research for new and innovative solutions. Given the increase in therapeutic options, clinicians and researchers will clearly benefit from the opportunity to be informed and to discuss the newest data and their implications for clinical practice.
This meeting aims at bridging the gap between the knowledge that is shared among experts in the field and the knowledge of healthcare professionals and clinicians in daily practice- an optimal setting for regional clinicians, researchers and pharmaceutical companies to meet each other and share knowledge.